For localized information and support, would you like to switch to your country-specific website for {0}?
cobas® EBV
Quantitative nucleic acid test for use on the cobas® 5800/6800/8800 systems
IVD
For in vitro diagnostic use.
Setting a new standard for transplant patients
The cobas® EBV test provides reliable, standardized, high-quality results for the improved management of transplant patients at risk of infection. The test is intended as an aid in the diagnosis and management of Epstein-Barr Virus (EBV) in transplant patients, with results used to guide treatment decisions.2 The test is for use on the automated cobas® 5800/6800/8800 systems.
Epstein-Barr virus
Epstein-Barr Virus (EBV) diseases, including EBV-associated post-transplant lymphoproliferative disorder (PTLD), remain important causes of morbidity and mortality in patients undergoing solid organ transplantation and hematopoietic cell transplantation.1 Early detection with best-in-class monitoring tools provides actionable results, which enable informed treatment decisions.
Use left and right arrow keys to scroll between the tabs
Overview
Technical documents
Access important product documentation including relevant certificates and other resources.
After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
cobas EBV test for cobas 5800/6800/8800 systems performance2
View full tablecobas EBV test for cobas 5800/6800/8800 systems performance2
Product specification |
Value |
Sample type |
EDTA plasma |
Minimum amount of sample required |
350 µL |
Sample processing volume |
200 µL |
Analytical sensitivity |
18.8 IU/mL |
Linear range |
35.0 IU/mL to 1E+08 IU/mL |
Genotypes detected |
Genotypes 1 and 2 |
Overall precision |
SD 0.02 - 0.17 log10 |
ACT Ecolabels: Solving for transparency in sustainability
ACT ecolabels are now available for cobas® molecular reagents & assays for use on cobas® 5800/6800/8800 systems and the cobas® liat system and assay portfolio.
Explore
This product has been awarded an ACT® Ecolabel, representing a virtual, quantified environmental impact score provided by My Green Lab, a non-profit organization dedicated to building a global culture of sustainability in science. My Green Lab partners with external experts from Verico to independently audit and validate sustainability claims – bringing trust, integrity and accountability towards the development of a global standard. Scoring is based on an assessment of data regarding energy use, materials, chemical hazards, and end-of-life options—plus an evaluation of the manufacturing facility and company commitments to reduce greenhouse gas emissions ACT Ecolabels are intended to provide a consistent benchmark to evaluate products for purchasing decision making. This certification reflects Roche’s commitment to reducing our environmental footprint and highlights our support for transparency in sustainability reporting. ACT Database
References
- Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652.
- F. Hoffmann-La Roche Ltd. cobas® EBV quantitative nucleic acid test for use on cobas® 5800/6800/8800 systems. Package insert (09478116001-04EN). (v4.0). 2024.